Cellular Immunotherapy for Men with Advanced Prostate Cancer
The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease. Provenge is manufactured by Seattle-based Dendreon Corp. Provenge is indicated for the treatment of asymptomatic or minimally symptomatic prostate cancer that has spread to other [...]
